NuCana (NCNA) Gains from Investment Securities (2019 - 2025)
NuCana's (NCNA) quarterly Gains from Investment Securities came in at $9311.2 in Q4 2025, up 120.73% year-on-year from $4218.4 in Q4 2024, and up 134.5% quarter-over-quarter from -$26987.2 in Q3 2025.
NuCana (NCNA) Gains from Investment Securities (2019 - 2025) Analysis & Trends
NuCana has disclosed Gains from Investment Securities across 7 years of filings, most recently posting $9311.2 for Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at $9311.2, up 120.73% year-over-year; the trailing twelve-month figure through Dec 2025 was -$141856.0 (up 50.21% YoY), and the FY2025 annual result was -$71199.6, up 75.02% from the prior year.
- Gains from Investment Securities came in at $9311.2 for Q4 2025 at NuCana, up from -$26987.2 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $9311.2 in Q4 2025 to a low of -$155802.2 in Q3 2023.
- The 5-year median for Gains from Investment Securities is -$79388.6 (2024), against an average of -$74157.4.
- Across the five-year window, Gains from Investment Securities plunged 59.03% in 2024 and jumped 120.73% in 2025, its largest moves.
- NuCana's Gains from Investment Securities stood at -$103431.9 in 2021, then gained by 11.12% to -$91929.9 in 2022, then gained by 14.94% to -$78192.6 in 2023, then surged by 42.55% to -$44922.6 in 2024, then jumped by 120.73% to $9311.2 in 2025.
- The last three Gains from Investment Securities figures came in at $9311.2 (Q4 2025), -$26987.2 (Q3 2025), and -$44922.6 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,311.16 |
| Dec 31, 2025 | 9,311.16 |
| Sep 30, 2025 | -26,987.24 |
| Sep 30, 2025 | -26,987.24 |
| Dec 31, 2024 | -44,922.56 |
| Dec 31, 2024 | -44,922.56 |
| Sep 30, 2024 | -79,257.31 |
| Sep 30, 2024 | -79,257.31 |
| Jun 30, 2024 | -79,519.91 |
| Jun 30, 2024 | -79,519.91 |
| Mar 31, 2024 | -81,185.16 |
| Mar 31, 2024 | -81,185.16 |
| Dec 31, 2023 | -78,192.57 |
| Dec 31, 2023 | -78,192.57 |
| Sep 30, 2023 | -155,802.23 |
| Sep 30, 2023 | -155,802.23 |
| Jun 30, 2023 | -52,557.25 |
| Jun 30, 2023 | -52,557.25 |
| Mar 31, 2023 | -51,051.40 |
| Mar 31, 2023 | -51,051.40 |